Lilly posts January 1 list prices for Mounjaro, Zepbound and Trulicity
Lilly's posted wholesale prices for Mounjaro, Zepbound and Trulicity set benchmarks, while what a patient pays still depends on insurance, savings cards or cash pricing.
Eli Lilly's drug pricing pages, using wholesale price data accessed January 1, 2026, show Mounjaro (tirzepatide) at $1,112.16 per monthly fill, Zepbound (tirzepatide) anywhere from $499 to $1,086.37 a fill, and Trulicity (dulaglutide) at $1,006.93 a month [1][2][3].
Those figures are the list price, which each page defines as the wholesale acquisition cost — what Lilly charges wholesalers [1][2][3]. The pharmacy counter price is a separate matter. All three pages say what a patient hands over depends mostly on the copay and coinsurance set by their insurance plan, plus pharmacy charges and whatever discounts or assistance apply [1][2][3].
Mounjaro's page carries one number and no range. A fill there means a month's supply, defined as four pens [1]. The page tells readers that insurance-plan-level pricing data "is not yet available" and that Lilly will publish average patient out-of-pocket costs after it arrives [1]. Commercially insured patients may qualify for a savings card; people covered by Medicaid, Medicare, Medigap, DoD, VA, TRICARE/CHAMPUS or a state assistance program do not [1]. Those with no coverage, or a plan that turns Mounjaro down, are pointed toward self-pay options that carry terms and conditions [1].
Zepbound's range is published without an explanation of what separates the bottom from the top [2]. The page also advertises cash prices for people buying directly from Lilly: $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 apiece at 10 mg, 12.5 mg and 15 mg, sold as a 4-count single-dose vial or a single-patient-use KwikPen [2]. Lilly notes this direct-to-patient pricing is not the wholesale figure, because only cash-paying patients can use it [2]. Separately, commercial plans that cover Zepbound can bring the cost of single-dose pens to as little as $25 for a one- or three-month supply through a savings card, with government beneficiaries left out and terms Lilly says it can change or end without notice [2].
Trulicity's page pairs its $1,006.93 monthly figure — four pens — with out-of-pocket results drawn from an internal review of HealthVerity data covering January to December 2024, accessed September 20, 2025 [3]. Among patients on employer or individual policies, roughly 40% paid nothing per prescription and 90% paid under $75; in Medicare about 70% paid nothing and 90% paid under $47; in Medicaid about 90% paid nothing [3]. Neither Mounjaro's nor Zepbound's page carries a similar breakdown [1][2].
What the updated pages do not show is where prices stood before. No earlier figures appear for comparison, and Lilly has not said whether any of the three changed [1][2][3]. The January 1 postings cover Mounjaro, Zepbound and Trulicity only; semaglutide brands such as Ozempic, Wegovy and Rybelsus, and orforglipron, do not appear on them [1][2][3].
Why it matters for patients
A list price is not an invoice. Two people filling the same prescription can owe very different sums because their plans set different cost sharing [1]. Trulicity's page offers the clearest illustration of that gap: a wholesale figure above $1,000 a month sits alongside claims data in which most insured patients paid nothing or a few dozen dollars [3]. That data covers Trulicity and 2024 claims, and no matching figures have been posted for the tirzepatide products [1][2].
Help programs come with boundaries. Mounjaro's savings card is limited to commercial insurance, and the exclusions cover Medicare and Medicaid enrollees [1]. Zepbound's card also leaves out government beneficiaries and can be changed or ended by Lilly at any time without notice [2].
Cash pricing moves with dose. Zepbound's direct-to-patient price starts at $299 for 2.5 mg and reaches $699 at the three highest strengths, so a change in dose can change the bill [2]. For people who qualify, Lilly Cares, a separate nonprofit, is described as supplying Lilly medicines at no cost, and the pricing pages link to Medicaid and Medicare copay resources [1][2][3].
What happens next
Lilly says it will share average patient out-of-pocket costs for Mounjaro once plan-level data is available, but has not given a date [1]. Nothing on the pages indicates when the posted figures will next be revised [1][2][3].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.